How to Get Evenity (Romosozumab) in Nevada

What Is Romosozumab and Why Does Access Matter in Nevada?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab both stimulates new bone building and reduces bone resorption, a dual mechanism unique among osteoporosis therapies [1]. The FDA approved Evenity in April 2019 for postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, or patients who have failed other available osteoporosis therapies [2].

Nevada presents specific access considerations. The state's Medicaid program does not cover Evenity, leaving roughly 700,000 Medicaid enrollees without this pathway [3]. Rural counties across Nevada, where specialist endocrinologists and rheumatologists are scarce, add geographic barriers. Clark County and Washoe County concentrate most bone-health specialists, so patients in Elko, Nye, or Humboldt counties often travel hours for in-person visits. Telehealth has become a practical workaround. Nevada law (NRS 629.515) permits prescribers to establish a provider-patient relationship via telehealth and write prescriptions for medications including biologics like romosozumab [4].

The ARCH trial (N=4,093) demonstrated that romosozumab for 12 months followed by alendronate reduced new vertebral fracture incidence by 48% compared to alendronate alone at 24 months [5]. These outcomes are why obtaining access, despite the bureaucratic hurdles, can be worth the effort for appropriately selected patients.

Who Can Prescribe Evenity in Nevada?

Any licensed prescriber with appropriate scope of practice can write an Evenity prescription in Nevada. That short list matters.

MDs and DOs hold unrestricted prescriptive authority. Endocrinologists and rheumatologists prescribe the majority of romosozumab nationally, but primary care physicians and geriatricians also initiate therapy when bone density results meet criteria. In Nevada, nurse practitioners with full prescriptive authority under NRS 632.237 can prescribe Evenity independently, as Nevada granted NPs full practice authority in 2013 [6]. Physician assistants may prescribe under a collaborative agreement with a supervising physician per NRS 630.275.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Romosozumab should be considered as initial therapy in patients at very high fracture risk, particularly those with recent fractures, very low T-scores, or fractures on prior therapy" [7]. This recommendation shapes which clinicians feel comfortable initiating therapy versus referring to a specialist. A primary care NP who identifies a T-score of -3.5 on DXA and a recent wrist fracture has sufficient clinical justification to start the prescription process without a specialist referral, though some insurance plans require specialist documentation for prior authorization.

For telehealth-specific prescribing, Nevada does not restrict the drug classes a telehealth provider can prescribe (with the exception of certain controlled substances). A board-certified endocrinologist licensed in Nevada can evaluate a patient via video visit, review uploaded DXA and lab results, and prescribe romosozumab. The prescription is then sent to a specialty pharmacy for fulfillment and patient training on self-injection or coordination with an infusion center for administration.

What Labs and Tests Are Required Before Starting?

Before any prescriber writes for Evenity, a defined set of labs and imaging must be completed. Skipping these creates both clinical risk and prior authorization denials.

The baseline requirements include a DXA scan with T-scores at the lumbar spine, femoral neck, and total hip. Most insurers require a T-score of -2.5 or lower at one or more sites, though some will approve at T-scores between -1.0 and -2.5 if the patient has a qualifying fracture history [8]. The FRAX score (10-year fracture probability) frequently appears on prior authorization forms. A 10-year major osteoporotic fracture risk of 20% or greater, or hip fracture risk of 3% or greater, typically meets the threshold [9].

Laboratory tests serve two purposes: safety screening and insurance documentation.

Required labs generally include serum calcium (romosozumab is contraindicated in hypocalcemia), 25-hydroxyvitamin D (levels should be above 30 ng/mL before initiating therapy, with supplementation if below), a comprehensive metabolic panel to assess renal function, and bone turnover markers such as serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide) [10]. P1NP specifically helps document the anabolic response during treatment, though not all insurers require it at baseline.

The FDA label carries a boxed warning regarding cardiovascular risk. Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [2]. Prescribers should document cardiovascular risk assessment. A recent lipid panel and blood pressure measurement become part of the chart, and some prior authorization forms explicitly ask whether the patient has a history of MI or CVA within 12 months.

For Nevada telehealth patients, labs and DXA must be completed at a local facility. Quest Diagnostics and Labcorp both operate draw sites across Nevada. DXA scans are available at imaging centers in Las Vegas, Reno, Henderson, and Sparks. Patients in more remote areas may need to travel to the nearest radiology center. Results can then be uploaded to the telehealth provider's portal for review.

How Prior Authorization Works in Nevada

Prior authorization is the single biggest bottleneck between prescription and first injection. Nearly every payer requires it for romosozumab.

Commercial insurers in Nevada (UnitedHealthcare, Anthem Blue Cross Blue Shield, Aetna, Cigna, and others) each maintain their own step-therapy protocols. The typical path requires documented failure of, intolerance to, or contraindication for at least one bisphosphonate (alendronate or risedronate) and sometimes denosumab before approving romosozumab [11]. "Failure" usually means a new fracture or continued bone density decline on therapy for at least 12 months.

Documentation the prescriber needs to submit includes the DXA report with T-scores, FRAX calculation, fracture history with imaging evidence, prior osteoporosis medication history (drug names, dates, reasons for discontinuation), the cardiovascular risk assessment, and baseline lab results. Missing even one element can trigger a denial.

Medicare Part B covers Evenity as a physician-administered drug when given in a clinic setting, or under Part B's incident-to billing when administered in a physician's office. Medicare Advantage plans may impose additional prior authorization requirements beyond traditional Medicare [12]. The Centers for Medicare & Medicaid Services (CMS) does not maintain a national coverage determination for romosozumab, so coverage falls to local Medicare Administrative Contractors (MACs). Noridian Healthcare Solutions, the MAC covering Nevada, processes these requests.

Nevada Medicaid does not cover Evenity as of 2026. Patients enrolled in Nevada Medicaid who meet clinical criteria for romosozumab have limited options: manufacturer patient assistance programs (Amgen's Evenity Access Program), clinical trials, or transitioning insurance coverage if eligible. Amgen's patient support program provides copay assistance for commercially insured patients and free drug for qualifying uninsured or underinsured patients, with income thresholds based on federal poverty level guidelines [13].

The timeline from prescription to first dose typically runs 2 to 4 weeks when prior authorization is approved on the first attempt. Denials add 2 to 6 weeks for the appeal process. Peer-to-peer reviews, where the prescribing physician speaks directly with the insurer's medical director, resolve a significant portion of initial denials.

Telehealth Pathways for Evenity in Nevada

Telehealth has changed how Nevada residents access specialty medications, and Evenity is no exception.

Nevada permits full telehealth prescribing under NRS 629.515, including for biologics and specialty medications [4]. A prescriber licensed in Nevada can conduct an initial evaluation via video, review labs and imaging, and electronically prescribe romosozumab. The state does not require an in-person visit before writing a specialty prescription, though individual insurance policies may have their own rules.

Several national telehealth platforms and endocrinology-focused practices serve Nevada patients. The key consideration is whether the telehealth provider will handle the prior authorization process. Specialty pharmacy coordination, benefits investigation, and appeals are time-intensive. Patients should confirm before their first visit that the telehealth practice manages the full access pipeline, not just the prescription itself.

For the injection, romosozumab is administered as two subcutaneous injections (two prefilled syringes of 105 mg each, for a total dose of 210 mg) once monthly [2]. While many patients receive injections in a clinic, self-administration at home is possible after proper training. Telehealth providers can arrange virtual injection training through the specialty pharmacy, and Amgen offers nurse educator programs where a trained nurse visits the patient's home for the first injection [13].

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and lead investigator on the FRAME trial, has noted: "The dual effect of romosozumab, increasing bone formation while decreasing bone resorption, produces gains in bone density that exceed those of any other available osteoporosis therapy" [14]. This clinical profile makes the access effort particularly meaningful for patients at imminent fracture risk.

Pharmacy Access and Fulfillment in Nevada

Romosozumab is a biologic manufactured exclusively by Amgen. It is not available through 503A compounding pharmacies, despite Nevada licensing 503A facilities. Compounding pharmacies cannot legally replicate patented biologics.

Evenity is dispensed through specialty pharmacies. The major specialty pharmacy networks operating in Nevada include CVS Specialty, Accredo (Express Scripts), OptumRx Specialty, and AllianceRx Walgreens. These pharmacies handle cold-chain shipping (romosozumab requires refrigeration at 2 to 8 degrees Celsius), patient enrollment, and injection training [2].

For patients receiving in-office administration, the prescriber's practice orders the drug through a buy-and-bill model under Medicare Part B, or through a specialty pharmacy for commercial plans. The medication is shipped directly to the prescribing clinic. Patients in rural Nevada areas where the prescriber is a telehealth provider may opt for home delivery through the specialty pharmacy, with self-injection after training.

The wholesale acquisition cost (WAC) of Evenity is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course [15]. Out-of-pocket costs vary widely. With commercial insurance after prior authorization approval, copays range from $0 to $150 per injection using Amgen's copay card. Medicare Part B patients typically pay 20% coinsurance after meeting the deductible, though supplemental insurance or Medigap policies can reduce this amount.

The ARCH Trial: Evidence Supporting Romosozumab

The evidence base matters for both clinical decision-making and insurance approval.

The ARCH trial, published in the New England Journal of Medicine in 2017, randomized 4,093 postmenopausal women with osteoporosis and a fragility fracture to receive either romosozumab 210 mg monthly for 12 months followed by alendronate, or alendronate alone for 24 months [5]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk 0.52 to 95% CI 0.40 to 0.68, P<0.001) compared to alendronate alone.

For clinical fractures (a composite of nonvertebral and symptomatic vertebral fractures), the romosozumab sequence reduced risk by 27% (hazard ratio 0.73 to 95% CI 0.61 to 0.87, P<0.001) [5]. Hip fracture risk was reduced by 38% (HR 0.62 to 95% CI 0.42 to 0.92). These results established romosozumab as the first-line anabolic option for patients at very high fracture risk.

The FRAME trial (N=7,180) compared romosozumab to placebo for 12 months, each followed by denosumab. At 12 months, romosozumab reduced new vertebral fractures by 73% compared to placebo (incidence 0.5% vs. 1.8%, P<0.001) [14]. Bone mineral density increased by 13.3% at the lumbar spine and 6.9% at the total hip over 12 months with romosozumab, compared to 0.0% and 0.3% with placebo.

The cardiovascular safety signal deserves attention. In ARCH, adjudicated serious cardiovascular adverse events occurred in 2.5% of romosozumab patients versus 1.9% of alendronate patients over 12 months [5]. This difference led to the FDA's boxed warning. The risk-benefit assessment should be individualized. For a 72-year-old woman with a T-score of -3.8, a recent vertebral fracture, and no cardiovascular history, the fracture risk reduction typically outweighs the cardiovascular signal.

Transitioning After the 12-Month Course

Romosozumab is not a maintenance therapy. The bone-forming effects diminish after 12 months, and discontinuation without follow-on antiresorptive therapy leads to rapid bone density loss.

The standard protocol is to transition to an antiresorptive agent after completing 12 monthly doses. Options include alendronate (70 mg weekly oral), zoledronic acid (5 mg IV once yearly), or denosumab (60 mg subcutaneous every 6 months) [7]. The ARCH trial specifically validated the romosozumab-to-alendronate sequence. Some clinicians prefer the romosozumab-to-denosumab sequence based on FRAME extension data showing continued BMD gains, though this path carries its own consideration: denosumab discontinuation causes rebound bone loss and requires careful planning for eventual transition [16].

Nevada patients on telehealth should coordinate the transition plan before the 12th dose. The follow-on prescription needs its own prior authorization, and starting that process at month 10 avoids a gap in therapy. A two-week lapse between romosozumab and an antiresorptive is unlikely to cause harm, but a gap of several months can erode the density gains achieved during the anabolic window.

Monitoring during and after treatment includes repeat DXA at 12 months (end of romosozumab) and again at 24 months (12 months into antiresorptive therapy). Bone turnover markers, particularly P1NP and CTX, can be checked at 3 and 6 months during romosozumab therapy to confirm anabolic response, though this is optional and not required by most insurers [10].

The 2020 AACE guidelines recommend repeating the cardiovascular risk assessment at each visit during romosozumab therapy and discontinuing the drug if a cardiovascular event occurs [7]. This monitoring can be performed during telehealth follow-up visits. Standard vital signs (blood pressure, heart rate) should be assessed locally, at a pharmacy kiosk or primary care office, and reported to the prescribing provider.